|
6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Suppliers list
|
|
| | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Basic information |
| Product Name: | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- | | Synonyms: | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)-;9(S)-Hexahydrocannabinol (CRM);9(S)-Hexahydrocannabinol | | CAS: | 36403-91-5 | | MF: | C21H32O2 | | MW: | 316.48 | | EINECS: | | | Product Categories: | | | Mol File: | 36403-91-5.mol | ![6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Structure](CAS/20210305/GIF/36403-91-5.gif) |
| | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Chemical Properties |
| Boiling point | 390.2±31.0 °C(Predicted) | | density | 0.993±0.06 g/cm3(Predicted) | | solubility | Acetonitrile: 10 mg/ml | | pka | 9.94±0.60(Predicted) |
| | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Usage And Synthesis |
| Description | 9(S)-Hexahydrocannabinol (CRM) is a certified reference material that is structurally similar to known phytocannabinoids.1 9(S)-Hexahydrocannabinol induces drowsiness, decreased motor activity, occasional partial ptosis, and occasional head drop, markers of psychotropic activity, in rhesus monkeys.2 This product is intended for research and forensic applications. | | Uses | 9(S)-Hexahydrocannabinol-d9 (9α-Hexahydocaabiol-d9, 11α-Hexahydocaabiol-d9, 9α-HHC-d9, 9(S)-HHC-d9, 11α-HHC-d9, tas-(6aR,9S,10aR)-HHC-d9) is deuterium labeled 9(S)-Hexahydrocannabinol[1]. | | References | [1] Lee, Y.R., and Xia, L. Efficient one-pot synthetic approaches for cannabinoid analogues and their application to biologically interesting (–)-hexahydrocannabinol and (+)-hexahydrocannabinol Tetrahedron Lett. 49(20),3283-3287(2008). [2] Mechoulam, R., Lander, N., Varkony, T.H., et al. Stereochemical requirements for cannabinoid activity J. Med. Chem. 23(10),1068-1072(1980). [3] KARIN LINDBOM. Human metabolism of the semi-synthetic cannabinoids hexahydrocannabinol, hexahydrocannabiphorol and their acetates using hepatocytes and urine samples[J]. Drug Testing and Analysis, 2024, 17 3: 372-386. DOI: 10.1002/dta.3740 [4] LIESL K. JANSSENS. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs[J]. Archives of Toxicology, 2024, 98 8: 2619-2630. DOI: 10.1007/s00204-024-03769-4 [5] UJVÁRY I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review[J]. Drug Testing and Analysis, 2023, 16 2: 127-161. DOI: 10.1002/dta.3519 |
| | 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9S,10aR)- Preparation Products And Raw materials |
|